Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Uveitis, Posterior
Interventions
DRUG

Fluocinolone Acetonide Intravitreal Implant 0.18 mg

YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.

Trial Locations (23)

16507

Erie Retina Research, LLC, Erie

21740

Cumberland Valley Retina Consultants, Hagerstown

30060

Marietta Eye Clinic, Marietta

33067

Advanced Research, Coral Springs

33544

Retina Specialists of Tampa, Wesley Chapel

37203

Tennessee Retina, Nashville

43623

Retina Vitreous Associates, Toledo

49546

Foundation for Vision Research, Grand Rapids

58104

Retina Consultants, Fargo

60304

Illinois Retina Associates, S.C., Oak Park

60616

Retinal Vitreal Consultants Ltd., Chicago

63017

Midwest Vision Research Foundation at Pepose Vision Institute, Chesterfield

77401

Retina Consultants of Texas, Bellaire

77494

Retina Consultants of Texas, Katy

78240

Medical Center Opthalmology Associates, San Antonio

78503

Valley Retina Institute, PA, McAllen

80228

Retina Associates of Colorado, Lakewood

91107

California Eye Specialists Medical Group, Pasadena

91203

Macula and Retina Institute, Glendale

92835

Retina Consultants of Orange County, Fullerton

95825

Retinal Consultants Medical Group, Sacramento

02114

Opthalmic Consultants of Boston, Boston

02451

Massachusets Eye Research and Surgery Institution, Waltham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

CBCC Global Research

NETWORK

lead

Alimera Sciences

INDUSTRY